Matica BioLabs to Conduct Contract Manufacturing and Quality Testing for CAR-NK Therapy
UCI Therapeutics Develops CAR-NK Therapy 'UCI-101' Utilizing the 'CellTaCT' Platform

Cha Biotech announced on April 1 that its subsidiary, Matica BioLabs, has signed a contract manufacturing agreement for CAR-NK cell therapy products with UCI Therapeutics, a company developing CAR-NK-based immunotherapy.

Representatives from Matica Biolabs and UCI Therapeutics are taking a commemorative photo at the biopharmaceutical production contract signing ceremony. Matica Biolabs

Representatives from Matica Biolabs and UCI Therapeutics are taking a commemorative photo at the biopharmaceutical production contract signing ceremony. Matica Biolabs

View original image

Under this agreement, Matica BioLabs will conduct contract manufacturing and quality testing for 'UCI-101', the CAR-NK therapy currently under development by UCI Therapeutics.


'UCI-101', being developed by UCI Therapeutics, is an immunotherapy for hematologic cancers, designed to simultaneously recognize the CD19 and CD22 antigens expressed on cancer cells. By targeting both antigens at once, this approach aims to overcome antigen loss issues and enhance therapeutic efficacy.


With this strategy, 'UCI-101' is expected to overcome the limitations of single-target CAR-T therapies. CAR-T therapies can lose effectiveness if cancer cells evade the specific target antigen.


UCI Therapeutics has independently developed the 'CellTaCT' platform, which enables genetic modification of NK cells to express CARs targeting solid tumors and to secrete proteins that modulate the tumor microenvironment, making treatment of solid tumors possible. The company is also developing cell and gene therapies for solid cancers using the 'CellTaCT' platform.


Byungjo Min, CEO of Matica BioLabs, stated, "We will ensure the stable production and supply of UCI Therapeutics' innovative CAR-NK therapy products, and continuously strengthen our competitiveness in the CDMO field for cell and gene therapies."



Sooyoung Jeong, CEO of UCI Therapeutics, said, "We highly value Matica BioLabs' experience in manufacturing CAR-T and CAR-NK therapies, as well as its capabilities in cell therapy manufacturing and quality management," adding, "There is strong potential for multifaceted collaboration in future clinical trials."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing